文献速递糖尿病

血糖异常与Index60作为1型糖尿病预防试验的诊断前终点

Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials.
PubMed 文献 · Diabetes Care · 2017-08-31

研究基于1型糖尿病TrialNet Pathway to Prevention研究参与者,评估血糖异常和Index60≥1.00作为1型糖尿病诊断前终点。结果提示,不伴Index60≥1.00的血糖异常是次优诊断前终点,而同时纳入血糖和C肽的指标如Index60≥1.00似乎更适合作为诊断前终点。

要点

  • 不伴Index60≥1.00的血糖异常是次优的1型糖尿病诊断前终点。
  • 包含血糖和C肽的指标如Index60≥1.00似乎更适合作为诊断前终点。
  • 在非进展者中,末次OGTT时IND/DYS-的1型糖尿病风险高于DYS/IND-。

核心结论

  • 研究结果提示,不伴Index60≥1.00的血糖异常是次优的1型糖尿病诊断前终点,而同时包含血糖和C肽水平的指标如Index60≥1.00似乎更适合作为诊断前终点。

研究设计与样本

  • 分析了两组队列:基线口服葡萄糖耐量试验(OGTT)血糖正常且发生血糖异常OGTT者,以及基线Index60<1.00 OGTT且发生Index60≥1.00 OGTT者。

主要发现

  • 1型糖尿病累积发生率在IND/DYS-后高于DYS/IND-后(P<0.01)。
  • 在血糖正常队列中,1型糖尿病累积发生率在DYS/IND+后高于DYS/IND-后(P<0.001)。
  • 在Index60<1.00队列中,1型糖尿病累积发生率在IND/DYS+后与IND/DYS-后无显著差异。
  • 在非进展者中,末次OGTT时1型糖尿病风险IND/DYS-高于DYS/IND-(P<0.001)。
  • DYS/IND-与年龄和30至0分钟C肽的风险比(HR)为正(两者P<0.001),而1型糖尿病与这些变量的HR为负(两者P<0.001);IND/DYS-和1型糖尿病与年龄和30至0分钟C肽的HR一致(均为负,所有P<0.01)。

关键数值与推荐

  • Index60≥1.00基于空腹C肽、60分钟血糖和60分钟C肽水平。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We assessed dysglycemia and a T1D Diagnostic Index60 (Index60) ≥1.00 (on the basis of fasting C-peptide, 60-min glucose, and 60-min C-peptide levels) as prediagnostic end points for type 1 diabetes among Type 1 Diabetes TrialNet Pathway to Prevention Study participants. RESEARCH DESIGN AND METHODS: Two cohorts were analyzed: 1) baseline normoglycemic oral glucose tolerance tests (OGTTs) with an incident dysglycemic OGTT and 2) baseline Index60 <1.00 OGTTs with an incident Index60 ≥1.00 OGTT. Incident dysglycemic OGTTs were divided into those with (DYS/IND+) and without (DYS/IND-) concomitant Index60 ≥1.00. Incident Index60 ≥1.00 OGTTs were divided into those with (IND/DYS+) and without (IND/DYS-) concomitant dysglycemia. RESULTS: The cumulative incidence for type 1 diabetes was greater after IND/DYS- than after DYS/IND- (P < 0.01). Within the normoglycemic cohort, the cumulative incidence of type 1 diabetes was higher after DYS/IND+ than after DYS/IND- (P < 0.001), whereas within the Index60 <1.00 cohort, the cumulative incidence after IND/DYS+ and after IND/DYS- did not differ significantly. Among nonprogressors, type 1 diabetes risk at the last OGTT was greater for IND/DYS- than for DYS/IND- (P < 0.001). Hazard ratios (HRs) of DYS/IND- with age and 30- to 0-min C-peptide were positive (P < 0.001 for both), whereas HRs of type 1 diabetes with these variables were inverse (P < 0.001 for both). In contrast, HRs of IND/DYS- and type 1 diabetes with age and 30- to 0-min C-peptide were consistent (all inverse [P < 0.01 for all]). CONCLUSIONS: The findings suggest that incident dysglycemia without Index60 ≥1.00 is a suboptimal prediagnostic end point for type 1 diabetes. Measures that include both glucose and C-peptide levels, such as Index60 ≥1.00, appear better suited as prediagnostic end points.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Nathan BM, Boulware D, Geyer S, et al. Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials. Diabetes Care. 2017. PMID: 28860125. doi:10.2337/dc17-0916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。